Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Added 257 days ago (04.01.2021)
Authors: Sheng, X., Yan, X., Wang, L., Shi, Y., Yao, X., Luo, H., Shi, B., Liu, J., He, Z., Yu, G., Ying, J., Han, W., Hu, C., Ling, Y., Chi, Z., Cui, C., Si, L., Fang, J., Zhou, A., Guo, J.
Read article